NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that the U.S. Food and Drug Administration has approved its Investigational New Drug (“IND”) application for Lucid-MS (Lucid-21-302), clearing the company to advance the patented, first-in-class multiple sclerosis candidate into Phase 2 clinical development. The planned randomized, double-blind, placebo-controlled study will evaluate efficacy, safety and tolerability in people with MS using clinical and radiological measures. Trial start-up activities, including site selection, are underway, with patient enrollment and drug administration expected to begin as quickly as possible.
Lucid-MS is designed to provide neuroprotection by inhibiting demyelination, differentiating it from existing MS therapies that primarily focus on modulating the immune system. The candidate targets protein arginine deiminase 2 (“PAD2”), an enzyme implicated in myelin degradation, and has demonstrated the ability to prevent and reverse myelin breakdown in preclinical models. Quantum BioPharma said Lucid-MS demonstrated a favorable safety profile and was well tolerated in prior Phase 1 trials in healthy participants. The company reported more than $10 million in cash, digital assets and liquid investments as of March 31, 2026.
To view the full press release, visit https://nnw.fm/HyWYH
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that the U.S. Food and Drug Administration has approved its Investigational New Drug (“IND”) application for Lucid-MS (Lucid-21-302), clearing the company to advance the patented, first-in-class multiple sclerosis candidate into Phase 2 clinical development. The planned randomized, double-blind, placebo-controlled study will evaluate efficacy, safety and tolerability in people with MS using clinical and radiological measures. Trial start-up activities, including site selection, are underway, with patient enrollment and drug administration expected to begin as quickly as possible.
Lucid-MS is designed to provide neuroprotection by inhibiting demyelination, differentiating it from existing MS therapies that primarily focus on modulating the immune system. The candidate targets protein arginine deiminase 2 (“PAD2”), an enzyme implicated in myelin degradation, and has demonstrated the ability to prevent and reverse myelin breakdown in preclinical models. Quantum BioPharma said Lucid-MS demonstrated a favorable safety profile and was well tolerated in prior Phase 1 trials in healthy participants. The company reported more than $10 million in cash, digital assets and liquid investments as of March 31, 2026.
To view the full press release, visit https://nnw.fm/HyWYH
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
